Generic Drug Producers – Discover Top Companies’ Revenue Prospects Now, Benefiting Your Influence What does the future hold for manufacturers and sellers of generic medicines? Visiongain’s new report shows you leading companies’ prospects to 2025. That study lets you discover results, trends, opportunities and revenue forecasts, helping you stay ahead in knowledge.
For leading producers and marketers of generic drugs, you find information on established and rising companies. Explore their sales potentials in the generics market, seeing from 2015 to 2025 the prospects of industry leaders. What revenues are possible?
Sales predictions and other data to help you stay ahead in competitive intelligence In our study you find analytical profiles of top generics producers. By region you analyse historical data, activities, revenue forecasts and growth rates. Discover qualitative analysis too. That work gives you 82 tables, 87 charts and two interviews with the industry.
Our new analysis shows you the most lucrative parts of the world industry for generic drugs. See today how you can benefit your research, analyses, decisions, proposals and presentations, also saving time and benefiting your reputation for insight.
Assessments of top companies – capabilities, results, competition and sales potentials Our report assesses 43 leading manufacturers of generic medicines worldwide. In general a company profile gives you the following information: • Discussion of activities, technologies and recent financial results • Assessment of developments – mergers and acquisitions (M&A), new products, outlooks, challenges and plans • Forecasting of generic drug revenues to 2025 (for 19 leading companies).
Discover capabilities, progress and prospects of top generics companies, grouped by region, helping you stay ahead in commercial knowledge and influence. Our study explains the changing generics industry from 2015 to 2025, including opportunities.
For the top 50 generic drug manufacturers in 2014, discover revenues and rankings. Also see top companies’ gross profit margins, EBITDA margins and historical revenue growth.
The following sections show how our new investigation helps your work.
North America – outlooks for leading generic drug producers and sellers First our report analyses 13 North American generics specialists and big pharma companies in that market, including these firms: • Mylan • Pfizer • Abbott • Hospira • Apotex • Par Pharmaceuticals.
In that analysis you find where revenue growth occurs and how high sales can go. Many opportunities remain, with high, expanding revenues possible from 2015.
Europe – prospects for leading generics players Our survey also shows you outlooks for 10 European generics specialists and pharmaceutical leaders in that industry, including these firms: • Novartis (Sandoz) • Actavis • Sanofi • Fresenius Kabi • Pharmstandard • Gedeon Richter • Stada Arzneimittel.
The report shows you how companies can seize opportunities and expand their businesses from 2015 to 2025. You also examine organisations competing for shares of that expanding, evolving market.
India – analysis of leading generic drug firms Our new work also assesses 10 Indian generic drug producers, including these firms: • Sun Pharmaceutical Industries • Dr. Reddy’s Laboratories • Lupin • Ranbaxy • Aurobindo • Glenmark • Wockhardt.
How much sales growth and geographical expansion can Indian generics companies achieve from 2015? Our study shows you revenue data, trends and prospects, examining what opportunities and potentials exist.
Producers from the rest of world – assess technologies, progress and prospects Our investigation also shows you outlooks for 10 generic drug makers based in other countries, including these companies: • Teva Pharmaceutical Industries • EMS • Aspen Pharmacare • Nichi-Iko • Abdi Ibrahim • Hypermarcas • Eurofarma • Sawai Pharmaceuticals.
Countries such as Japan, Brazil and China will become increasingly important for generic drug development, production and sales from 2015 to 2025, our analyses show.
That work explains forces shaping the generics market and industry, helping you explore changes, challenges and opportunities. Discover what the future holds.
Issues affecting generic drug development, manufacturing and sales Our report discusses issues and events affecting that industry and market from 2015, including these forces: • Specialty generics – difficult-to-produce medicines with high profit margins • Shift towards innovative and improved drugs, via expanding R&D budgets • Mergers and acquisitions (M&A) influencing that expanding healthcare market • Big pharma firms targeting generics – diversification of product portfolios • International expansion – targeting developed and developing national markets • Intellectual property – regulations, challenges and developments • Biosimilars – opportunities for generic and originator drug companies.
There you explore the generic drug industry’s strengths, weaknesses, opportunities and threats. With our study you discover what the future holds for top generic drug producers.
You also gain our interviews with Sanofi Generics and the Generic Pharmaceutical Association (GPhA). Hear what participants think, say and do, helping you stay ahead.
Ways Top Generic Drug Producers – Leading Companies and Forecasts 2015-2025 – Prospects for Development, Manufacturing and Business Expansion helps In particular, our new analysis benefits your work in these five main ways: • Profiles of 43 generics companies – assess product ranges, strategies and sales results, also gaining revenue forecasts to 2025 for 19 organisations • Competition and opportunities – explore what shapes the generic drugs market’s future, especially companies’ prospects for sustaining and expanding business • Analysis of what benefits and restrains generic drug makers – assess challenges and strengths, helping you compete and gain advantages • Reviews of established competitors and rising players in the generics sector – explore needs, competition, technologies and outlooks for future success • Interviews with authorities – discover what participants in the industry think, say and do, helping you stay ahead in commercial knowledge.
That report, by Visiongain’s in-house analysts in the UK, gives information to benefit your work, saving you hassle and time. You gain data leading companies depend on.
Knowledge found nowhere else, helping your research, analyses and decisions Our investigation gives independent analysis. You receive competitive intelligence found only in that report, discovering generics companies with the most commercial promise.
With our new survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions. Also find how you can save time and gain in recognition for insight, benefiting your authority.
Predictions for generic drug production and sales – gain by trying our study now Our new analysis shows you data, trends, opportunities and sales forecasts for top producers and sellers of generic drugs. Avoid missing out – please get our report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Introduction to this Survey 1.2 Main Report Findings 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Questions Answered by This Analytical Report 1.6 Who is This Report For? 1.7 Methods of Research and Analysis 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2. Top 50 Generic Drug Manufacturers 2.1 Top 50 Generic Drug Manufacturers: Revenues and Ranking, 2014 2.2 Top 50 Generic Drug Companies: Revenue Analysis, 2014 2.3 Top 50 Generic Drug Companies Regional Distribution, 2014 2.4 Report Coverage 2.5 Report Complexity 2.5.1 Obtaining Data from Private Companies 2.5.2 Financial Years Variability 2.5.3 Generics Revenue Identification 2.5.4 Defining Generics 1: Difference Between Biosimilars and Generics 2.5.5 Defining Generics 2: ‘Super-Generics’ and APIs 2.5.6 Defining Generics 3: Rx and OTC
3. Top North American Generic Drug Manufacturers: Activities and Prospects, 2015-2025 3.1 Companies Covered in this Chapter 3.2 Leading US Generic Drug Manufacturers: Financial Performance Outline, 2014 3.3 Mylan: Number One US Manufacturer of Generic Drugs: Company Overview, 2015 3.3.1 Mylan Historical Performance and Financial Results Analysis, 2015 3.3.2 Mylan Generic Drugs Revenue Forecast, 2015-2025 3.3.3 First Class II Transdermal Approval Consolidates Mylan’s Top Status in the US Market 3.3.4 Tender System Hurts Mylan’s German Market Share but the Company Retains its Australian Dominance 3.3.5 Mylan’s Focus on Complex Generics: Reasons and Causes 3.3.6 Mylan’s Generic Portfolio Remains the Company’s Core Strength 3.3.7 Mylan’s Winning Acquisition Strategy 3.3.8 Mylan Acquired Abbott: Towards Scale Economies and Vertical Integration 3.3.9 Mylan’s Potential Acquisition Plans - Outlook 3.4 Pfizer - The Leading Research-Based Pharmaceutical: Company Overview, 2015 3.4.1 Pfizer Historical Performance and Financial Results Analysis, 2015 3.4.2 Pfizer Generic Drugs Revenue Forecast, 2015-2025 3.4.3 Pfizer Internationalization and Restructuring Strategy 3.4.4 Pfizer’s Acquisition of Hospira: A Solution for Boosting the Generic Revenue Stream? 3.4.5 Prospects for Pfizer’s Generic Drugs Business 3.5 Abbott: Company Overview, 2015 3.5.1 Abbott Business Segments Performance 3.5.2 Abbott Historical Performance and Financial Results Analysis, 2015 3.5.3 Abbott Generic Drugs Revenue Forecast, 2015-2025 3.5.4 Abbott’s Acquisitions: Overview and Analysis, 2010-2014 3.5.5 Abbott’s Sale of its Overseas Branded Generic Business: Implications 3.5.6 Future Prospects for Abbott Generic Drugs Business 3.6 Hospira: Company Overview, 2015 3.6.1 Integrated Infusion Therapies and Other Hospira Businesses 3.6.2 Hospira - Injectable Expert Among the Top 10 Generic Companies Acquired by Pfizer 3.7 Apotex: Company Overview, 2015 3.7.1 Apotex Expansion to Europe and Beyond 3.7.2 Apotex Drives Business Diversification Through R&D 3.8 Par Pharmaceuticals: Company Overview, 2015 3.8.1 Par Pharmaceuticals’ Acquisition of JPH Group Holdings 3.8.2 Concentrated Generic Revenue Stream and Over 60 Generic Prescription Drugs 3.8.3 Buy Out of Indian Ethics Bio Lab Demonstrates Par’s Interest in Niche Products 3.9 Valeant Pharmaceuticals: Company Overview, 2015 3.9.1 Valeant: A Major Challenger in the Emerging Markets 3.9.2 Branded Generics are Crucial to Valeant’s Emerging Market Ambitions 3.9.3 Valeant Implements Acquisition Strategy to Boost Revenues 3.9.4 Valeant Generic Drugs Revenue Forecast, 2015-2025 3.10 Endo Pharmaceuticals: Company Overview, 2015 3.10.1 Endo: Pain Expertise in Branded and Generic Drugs 3.10.2 Endo’s Expansion on the South African Market 3.10.3 Performance Analysis on Endo’s Qualitest Business 3.10.4 Future Prospects for Endo Pharmaceuticals Generic Drugs Business 3.10.5 Endo Generic Drugs Revenue Forecast, 2015-2025 3.11 Pharmascience - Another Major Canadian Player: Company Overview, 2015 3.11.1 Over 200 Generic Product Families 3.11.2 Korean Venture Driving Diversification for Pharmascience 3.12 Mallinckrodt: Company Overview, 2015 3.12.1 Mallinckrodt Generics: Valuable Addition to the Company’s Portfolio 3.12.2 Reclassification of Methylphenidate ER Products: Effects on Mallinckrodt’s Income 3.12.3 What is Mallinckrodt’s Advantage Against Strong Competition? 3.12.4 Partnerships and Acquisitions: Crucial for Mallinckrodt’s Rapid Expansion 3.13 Akorn Pharmaceuticals: Company Overview, 2015 3.13.1 Akorn Acquisition of Small Companies: A Strategic Shift Towards Broad Market Reach 3.13.2 Akorn Strengthens its Position on the US Ophthalmology Market 3.14 Alvogen - A Privately-Owned US Company is the One to Watch: Company Overview, 2015 3.14.1 Alvogen Unique Business Model Proves Good Results 3.14.2 Alvogen Target is to Become Top 10 Global Generic Player 3.15 Sagent Pharmaceuticals - One of the Fastest Growing Providers of Specialty Generics in the US: Company Overview, 2015 3.15.1 Will Sagent’s Different Business Model Achieve Growth?
4. Top European Generic Drug Manufacturers: Activities and Prospects, 2015-2025 4.1 Companies Covered in this Chapter 4.2 Leading European Generic Drug Manufacturers: Financial Performance Outline, 2014 4.3 CEE Markets Home to Many Big Generic Contenders 4.4 Novartis (Sandoz) - the World’s Second Largest Generic Pharmaceutical Company: Overview, 2015 4.4.1 Novartis (Sandoz) Historical Performance and Financial Results Analysis, 2015 4.4.2 Novartis (Sandoz) Generic Drugs Revenue Forecast, 2015-2025 4.4.3 Novartis (Sandoz) Key Developments Analysis, 2015 4.4.4 Europe is the Main Market for Sandoz 4.4.5 Emphasis on Complex, Differentiated Generics and Biosimilars 4.4.6 Future Prospects for Novartis Generic Drugs Business 4.5 Actavis: Company Overview, 2015 4.5.1 Actavis Historical Performance and Financial Results Analysis, 2015 4.5.2 Actavis Generic Drugs Revenue Forecast, 2015-2025 4.5.3 Implications of Actavis Large Product Portfolio 4.5.4 Actavis Customized Commercial Model for International Markets 4.5.5 Merger Creates New Force in the Generic Drug Industry 4.5.6 Actavis Acquisition of Forest Laboratories: Move Towards Specialty Pharmaceuticals 4.5.7 The Acquisition of Auden McKenzie Will Add More than 150 Products to Actavis Product Line 4.5.8 Actavis Acquired Allergan with Aim to be a Top 10 Pharmaceutical Company 4.6 Sanofi: Company Overview, 2015 4.6.1 Sanofi Historical Performance and Financial Results Analysis, 2015 4.6.2 Sanofi Generic Drugs Revenue Forecast, 2015-2025 4.6.3 Adaptive Business Model for Sanofi’s Generic Drug Division 4.6.4 Zentiva Benefits from Strong Presence in the EU Market 4.6.5 Future Prospects for Sanofi Generics 4.7 Fresenius Kabi - Leading Generic Intravenous Drug Player: Company Overview, 2015 4.7.1 Intra Venous Drugs: The Main Product Line for Fresenius Kabi 4.7.2 Fresenius Kabi Will Continue to Expand 4.8 Pharmstandard - The Biggest Russian Pharmaceutical Manufacturer: Company Overview, 2015 4.8.1 Acquisitions Strengthen Pharmstandard Manufacturing and Product Base 4.8.2 Pharmstandard Benefits from Strong Organic Production Capacity 4.8.3 Future Prospects for Pharmstandard Generic Drugs Business 4.8.4 Pharmstandard Generic Drugs Revenue Forecast, 2015-2025 4.9 Gedeon Richter - Hungarian Leader Looking Further Afield: Company Overview, 2015 4.9.1 Female Health and Fertility Segments Form Core Strengths for Gedeon Richter 4.9.2 Specialisation Strategy for Further Growth 4.9.3 A Pan-European Pharmaceutical Presence for the Future? 4.9.4 Gedeon Richter Generic Drugs Revenue Forecast, 2015-2025 4.10 Krka - Slovenian Generic Giant Active in 70+ Countries: Company Overview, 2015 4.10.1 Prescription Generics: Krka’s Major Focus 4.10.2 Russia is the Largest National Market for Krka, but for How Long? 4.10.3 Krka Generic Drugs Revenue Forecast, 2015-2025 4.11 Stada Arzneimittel - Major Presence in Germany and Central Europe: Company Overview, 2015 4.11.1 Negative Effect from the CIS Region Crisis 4.11.2 Strong Product Development with Over 600 Product Launches in 2014 4.11.3 Stada Targets the Biosimilar Sector with Promising Deals 4.11.4 Stada Arzneimittel Generic Drugs Revenue Forecast, 2015-2025 4.12 Perrigo: Company Overview, 2015 4.12.1 Perrigo Drives Generic Segment Growth through Acquisitions, but Will it be Acquired Itself? 4.12.2 Rx Pharmaceuticals: Main Contributors to Perrigo’s Revenue Stream 4.13 Polpharma - Poland’s Generic Powerhouse: Company Overview, 2015 4.13.1 Polpharma’s Continuous Product Portfolio Enlargement 4.13.2 Strong Regional Presence in Poland, Russia and Kazakhstan 4.13.3 Acquisition Increases Polpharma Dominance in the Polish Market
5. Top Indian Generic Drug Manufacturers: Activities and Prospects, 2015-2025 5.1 Companies Covered in This Chapter 5.2 India: Generics Supplier to the World 5.3 Top 10 Indian Generic Drug Manufacturers: Financial Performance Outline, 2014 5.4 Sun Pharmaceutical - Leader in the Indian Generic Drug Market, Company Overview, 2015 5.4.1 Sun Has a Leading Presence in the Generic Export Market 5.4.2 Mega Acquisitions to Enlarge Sun’s Operations? 5.4.3 Sun Pharmaceutical Generic Drugs Revenue Forecast, 2015-2025 5.5 Dr. Reddy’s Laboratories: Company Overview, 2015 5.5.1 At the Forefront of the Indian Generic Boom: Dr. Reddy’s Revenue Exceeded $2bn in 2014 5.5.2 North America and Russia are the Largest Export Markets for Dr. Reddy’s 5.5.3 Alliance with GlaxoSmithKline 5.5.4 Dr. Reddy’s Early Leadership in Biosimilar Antibodies 5.5.5 Dr. Reddy’s: Generic Drugs Revenue Forecast, 2015-2025 5.6 Lupin - The Most Successful Indian Generic Firm in the US Market: Company Overview, 2015 5.6.1 Lupin’s Continuous Portfolio Growth and Focus on Complex Injectables 5.6.2 Strong R&D Investment in New Delivery Systems and Original Products 5.6.3 Lupin Generic Drugs Revenue Forecast, 2015-2025 5.7 Cipla - Mumbai Based Generic Giant: Company Overview, 2015 5.7.1 Generic Copaxone: A Major Product Launch for Cipla 5.7.2 Cipla’s Leadership in Anti-Retroviral Drugs and Focus on Key Markets 5.7.3 Chronic Disease: A Significant Target for Cipla 5.7.4 Cipla Generic Drugs Revenue Forecast, 2015-2025 5.8 Ranbaxy -The Second Largest Indian Generic Manufacturer with Sales in 150+ Countries: Company Overview, 2015 5.8.1 Dermatological Therapeutics: Targeted Area of Growth for Ranbaxy 5.8.2 ANDA Applications Giving Promising Opportunities 5.8.3 High Income Stream from the Emerging Markets 5.8.4 Merger with Sun 5.9 Aurobindo – The Largest FDA APIs Supplier, Moved Into Original Drugs: Company Overview, 2015 5.9.1 High-Margin Specialty Generics 5.9.2 ANDA Filings and Approvals by Region, 2014 5.9.3 CRAMS Opportunities 5.10 Glenmark - Specialty Company Still Leveraging Generic Growth: Overview, 2015 5.10.1 Generics Remain Part of Global Growth Strategy for Glenmark 5.10.2 Glenmark Benefits from Africa and Middle East Exports Boom 5.10.3 Glenmark Generic Drugs Revenue Forecast, 2015-2025 5.11 Wockhardt -Increasing Presence in US and Europe Generics Market: Company Overview, 2015 5.11.1 US Market Growth in 2014 5.11.2 Biosimilars, Novel Delivery Systems and Original Drugs will Drive Growth for Wockhardt 5.12 Cadila - Leader in Indian Cardiovascular Market: Company Overview, 2015 5.12.1 Biochem Acquisition Boosts Cadila’s Revenue 5.12.2 Increasing Presence in the US Market 5.12.3 Cadila: A Future Biosimilar Force? 5.13 Ipca Laboratories - One of Top 10 Indian Pharma Exporters: Company Overview, 2015 5.13.1 Fast Development Due to Niche Strategic Approach
6. Top Generic Drug Manufacturers from the Rest of the World: Activities and Prospects, 2015-2025 6.1 Companies Covered in this Chapter 6.2 Leading Rest of the World Generic Drug Manufacturers: Financial Performance Outline, 2014 6.3 Japanese and Brazilian Generic Environment Particularly Significant to the Global Generic Drug Market 6.4 Teva Pharmaceutical Industries: Company Overview of the World’s Generic Industry Leader, 2015 6.4.1 Teva Historical Performance and Financial Results Analysis, 2010-2014 6.4.2 Teva Generic Drugs Revenue Forecast, 2015-2025 6.4.3 Teva’s Global Presence 6.4.4 How did Teva Achieve its Success? 6.4.5 Teva Operational Strategy: Focus on Cost Reduction 6.4.6 The US Market Stagnates but Teva Sustains its Strong Penetration 6.4.7 From Volume to Value Driven Strategy in the European Markets 6.4.8 Teva Strengthens its Position in the Central Nervous System Market Through the Acquisition of Auspex Pharma 6.4.9 Will Mylan Eventually Join Teva’s Long Acquisition List? 6.4.10 Future Prospects for Teva Generic Drugs Business 6.5 EMS - Leading the South American Generic Market: Company Overview, 2015 6.5.1 First Brazilian Company to Export Generics to Europe 6.5.2 EMS Has the Most Advanced Latin American R&D Base 6.6 Aspen Pharmacare - South African Giant Continues to Expand: Company Overview, 2015 6.6.1 Ten-Year CAGR to 2014 Exceeds 25% 6.6.2 Philippines Added to Areas of Activity 6.6.3 Continuing Over 30% Dominance in South Africa Generic Market 6.6.4 Asia-Pacific and International Business Main Revenue Contributors in 2014 6.6.5 Europe/CIS and Latin America: Another Major Growth Opportunity for Aspen 6.6.6 Aspen Generic Drugs Revenue Forecast, 2015-2025 6.7 Nichi-Iko: Company Overview, 2015 6.7.1 More Than 900 Generic Products in Nichi-Iko Portfolio 6.7.2 Nichi-Iko Venture with Sanofi Complements Strategy 6.8 Abdi Ibrahim: Turkey’s Leading Pharmaceutical Company 6.8.1 Large Product Portfolio Helps to Sustain Market Position 6.8.2 Abdi Ibrahim has a Vast International Scope 6.9 Hypermarcas SA - Brazilian Pharmaceutical and OTC Giant: Company Overview, 2015 6.9.1 Price Increase and High Profit Margins: Would they be Sustainable? 6.10 Eurofarma - Rapidly-Growing Generics Power in Brazil: Company Overview, 2015 6.10.1 Eight Diversified Business Divisions 6.10.2 M&A Extending Latin American Reach for Eurofarma 6.11 Taro Pharmaceuticals - The Second Largest Israeli Pharmaceutical Manufacturer: Company Overview, 2015 6.11.1 FDA Corticosteroid Spray Approval Boosts Taro’s Portfolio in 2014 6.12 Towa Pharmaceuticals - Another Big Japanese Player: Company Overview, 2015 6.12.1 Large Number of Generic Products in Towa’s Portfolio 6.12.2 Towa’s Broad and Expanding Production Capacity 6.13 Sawai Pharmaceuticals - Osaka-Based Generic Leader: Company Overview, 2015 6.13.1 Annual manufacturing Capacity of 10bn Tablets 6.13.2 Cardiovascular Drugs are the Most Significant Therapeutic Area for Sawai 6.13.3 M&A Boosts Sawai’s R&D
7. Interviews from Our Survey 7.1 Interview with Jean-Marie Arnaud, Senior Vice President and Head of Sanofi Generics 7.1.1 Sanofi Generics Act with the Expertise of Sanofi Group 7.1.2 Sanofi Uses Innovative and Adapted Business Model Worldwide 7.1.3 Increasing Revenues for Sanofi Generics as the Company Continues to Focus on Emerging Markets and Portfolio Enlargement 7.1.4 A Generic Product is no Longer Just a Pure Copy of an Original 7.1.5 The Usage of Generic Medicines in Europe Can Still be Optimised 7.1.6 A Combination of Strategies Proves Successful in the Generics Industry 7.2 Interview with a Representative of the Generic Pharmaceutical Association (GPhA) 7.2.1 86% of all Prescriptions in the US are for Generic Drugs 7.2.2 Patent Settlements Provide Higher Savings and Early Market Entry for Generics 7.2.3 The Cost Burden will Increase if the Generic Drug Labelling Rule Changes 7.2.4 Biosimilars – the New Target for Generic Drug Manufacturers
8. Conclusions 8.1 Companies’ Growth Strategies 8.2 Why are Big Pharma Companies Targeting Generics? 8.3 Watson and Actavis Merger: The First Major Consolidation for the Generic Drug Industry 8.4 The Changing Dynamics of the Generic Drug Companies 8.5 Big Pharma Business Models Evolve 8.6 Biosimilars Will Have a Transformative Effect on Both Generic and Originator Drug Companies 8.7 Complex Generics with High Entry Barriers Continue to Increase in Importance 8.8 Future Trends for Generic Drug Producers – What’s Possible?
List of Tables Table 1.1 Currency Exchange Rates to $US Table 2.1 Top 50 Generic Drug Manufacturers: Revenues ($m) and Ranking 1-25, 2014 Table 2.2 Top 50 Generic Drug Manufacturers: Revenues ($m) and Ranking 26-50, 2014 Table 2.3 Top 50 Generic Drug Manufacturers: Revenue ($m) and Market Share (%) According to Group Rank, 2014 Table 2.4 Regional Distribution of the Top 50 Companies, 2014 Table 3.1 Top 10 North American Generic Drug Manufacturers: Revenues ($m) and Ranking, 2014 Table 3.2 Mylan: Company Overview, 2015 Table 3.3 Mylan: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014 Table 3.4 Mylan: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 3.5 Pfizer: Company Overview, 2015 Table 3.6 Pfizer: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014 Table 3.7 Pfizer: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 3.8 Abbott: Company Overview, 2015 Table 3.9 Abbott: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014 Table 3.10 Abbott: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 3.11 Hospira: Company Overview, 2015 Table 3.12 Apotex: Company Overview, 2015 Table 3.13 Par Pharmaceutical: Company Overview, 2015 Table 3.14 Valeant Pharmaceuticals: Company Overview, 2015 Table 3.15 Valeant: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 3.16 Endo Pharmaceuticals: Company Overview, 2015 Table 3.17 Endo: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 3.18 Pharmascience: Company Overview, 2015 Table 3.19 Mallinckrodt: Company Overview, 2015 Table 3.20 Akorn Pharmaceuticals: Company Overview, 2015 Table 3.21 Alvogen: Company Overview, 2015 Table 3.22 Sagent Pharmaceuticals: Company Overview, 2015 Table 4.1 Top 10 European Generic Manufacturers: Revenues ($m) and Ranking, 2014 Table 4.2 Novartis (Sandoz): Company Overview, 2015 Table 4.3 Novartis: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014 Table 4.4 Novartis: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 4.5 Actavis: Company Overview, 2015 Table 4.6 Actavis: Historical Generic Drugs Revenues ($m), AGR (%), 2011-2014 Table 4.7 Actavis: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 4.8 Sanofi: Company Overview, 2015 Table 4.9 Sanofi: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014 Table 4.10 Sanofi: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 4.11 Fresenius Kabi: Company Overview, 2015 Table 4.12 Pharmstandard: Company Overview, 2015 Table 4.13 Pharmstandard: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 4.14 Gedeon Richter: Company Overview, 2015 Table 4.15 Gedeon Richter: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 4.16 Krka: Company Overview, 2015 Table 4.17 Krka: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 4.18 Stada: Company Overview, 2015 Table 4.19 Stada: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 4.20 Perrigo: Company Overview, 2015 Table 4.21 Polpharma: Company Overview, 2015 Table 5.1 Top 10 Indian Generic Manufacturers: Revenues ($m) and Ranking, 2014 Table 5.2 Sun Pharmaceutical: Company Overview, 2015 Table 5.3 Sun Pharmaceutical: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 5.4 Dr. Reddy’s: Company Overview, 2015 Table 5.5 Dr. Reddy’s: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 5.6 Lupin: Company Overview, 2015 Table 5.7 Lupin: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 5.8 Cipla: Company Overview, 2015 Table 5.9 Cipla: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 5.10 Ranbaxy: Company Overview, 2015 Table 5.11 Ranbaxy: ANDA Filings and Approvals by Region, 2014 Table 5.12 Aurobindo: Company Overview, 2015 Table 5.13 Aurobindo: ANDAs Filings and Approvals by Region, 2014 Table 5.14 Glenmark: Company Overview, 2015 Table 5.15 Glenmark: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 5.16 Wockhardt: Company Overview, 2015 Table 5.17 Cadila: Company Overview, 2015 Table 5.18 Ipca: Company Overview, 2015 Table 6.1Top 10 Rest of the World Generic Drug Manufacturers, Revenues ($m) and Ranking, 2014 Table 6.2 Teva: Company Overview, 2015 Table 6.3 Teva: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014 Table 6.4 Teva: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 6.5 Teva: Revenue Breakdown (%) by Region, 2014 Table 6.6 Teva: New Generic Drugs Launches by Region, 2014 Table 6.7 Teva: Annual Revenue Change (%) in EU5 Countries, 2013-2014 Table 6.8 EMS: Company Overview, 2015 Table 6.9 Aspen: Company Overview, 2015 Table 6.10 Aspen: Generic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2015-2025 Table 6.11 Nichi-Iko: Company Overview, 2015 Table 6.12 Abdi Ibrahim: Company Overview, 2015 Table 6.13 Hypermarcas: Company Overview, 2015 Table 6.14 Eurofarma: Company Overview, 2015 Table 6.15 Taro Pharmaceutical: Company Overview, 2015 Table 6.16 Towa Pharmaceutical: Company Overview, 2015 Table 6.17 Sawai Pharmaceutical: Company Overview, 2015
List of Figures Figure 2.1 Top 50 Generic Drug Manufacturers: Revenues ($m), 2014 Figure 2.2 Generic Drug Manufacturers: Revenue ($m) Comparison by Group Rank, 2014 Figure 2.3 Top 50 Generic Drug Manufacturers: Market Share (%) Amongst the Top 50 Companies According to Group Rank, 2014 Figure 2.4 Top 10 Generic Drug Manufacturers: Market Share (%) Among the Top 50 Companies, 2014 Figure 2.5 Regional Balance Among the Top 50 Generic Drug Manufacturers, 2014 Figure 2.6 Biosimilars and Generics: Overview, 2015 Figure 3.1 Top 10 North American Generic Drug Manufacturers: Revenues ($m), 2014 Figure 3.2 Leading North American Generic Drug Manufacturers: Gross Profit Margin (%), 2014 Figure 3.3 Leading North American Generic Drug Manufacturers: EBITDA Margin (%), 2014 Figure 3.4 Leading North American Generic Drug Manufacturers: Revenue Growth (%), 2013-2014 Figure 3.5 Mylan: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014 Figure 3.6 Mylan: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 3.7 Mylan: Number of Generic Products on Leading European Markets, 2014 Figure 3.8 Mylan: Revenue Breakdown (%) by Business Segment, 2014 Figure 3.9 Mylan: Revenue Breakdown (%) by Therapeutic Area, 2014 Figure 3.10 Pfizer: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014 Figure 3.11 Pfizer: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 3.12 Abbott: Revenue Breakdown (%) by Business Segment, 2014 Figure 3.13 Abbott: Historical Generic Drugs Revenue ($m), AGR (%), 2010-2014 Figure 3.14 Abbott: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 3.15 Valeant: Revenue Breakdown (%) by Business Segment, 2014 Figure 3.16 Valeant: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 3.17 Endo: Revenue Breakdown (%) by Business Segment, 2014 Figure 3.18 Endo: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 3.19 Akorn’s Major Acquisition: Overview of the Reasons, 2015 Figure 4.1 Top 10 European Generic Manufacturers: Revenues ($m), 2014 Figure 4.2 Leading European Generic Drug Manufacturers: Gross Profit Margin (%), 2014 Figure 4.3 Leading European Generic Drug Manufacturers: EBITDA Margin (%), 2014 Figure 4.4 Leading European Generic Drug Manufacturers: AGR (%), 2013-2014 Figure 4.5 Novartis: Revenue Breakdown by Business Segment, 2014 Figure 4.6 Novartis: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014 Figure 4.7 Novartis: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 4.8 Sandoz: Revenue Breakdown by Region, 2014 Figure 4.9 Sandoz: Revenue Breakdown by Business Segment, 2014 Figure 4.10 Actavis Sales Breakdown (%), 2014 Figure 4.11 Actavis: Historical Generic Drugs Revenues ($m), AGR (%), 2011-2014 Figure 4.12 Actavis: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 4.13 Actavis Sales Breakdown (%), 2014 Figure 4.14 Sanofi: Generic Drugs Revenue Breakdown by Region, 2014 Figure 4.15 Sanofi: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014 Figure 4.16 Sanofi: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 4.17 Pharmstandard: Revenue Breakdown by Business Segment, 2014 Figure 4.18 Pharmstandard: Export Sales Breakdown by Country, 2014 Figure 4.19 Pharmstandard: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 4.20 Gedeon Richter: Revenue Breakdown by Therapeutic Segment, 2014 Figure 4.21 Gedeon Richter: Revenue Breakdown by Country, 2014 Figure 4.22 Gedeon Richter: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 4.23 Krka: Revenue Breakdown by Business Segment, 2014 Figure 4.24 Krka: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 4.25 Stada: Revenue Breakdown (%) by Business Segment, 2014 Figure 4.26 Stada: Revenue Breakdown by Region, 2014 Figure 4.27 Stada: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 4.28 Perrigo Company: Revenue Breakdown by Business Segment, 2014 Figure 5.1 Top 10 Indian Generic Manufacturers: Revenues ($m), 2014 Figure 5.2 Top 10 Indian Generic Drug Manufacturers: Gross Profit Margin (%), 2014 Figure 5.3 Top 10 Indian Generic Drug Manufacturers: EBITDA Margin (%), 2014 Figure 5.4 Top 10 Indian Generic Drug Manufacturers: Revenue AGR (%), 2013-2014 Figure 5.5 Sun Pharmaceutical: Revenue Breakdown (%) by Business Segment, 2014 Figure 5.6 Sun Pharmaceutical: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 5.7 Dr. Reddy’s: Revenue Breakdown (%) by Business Segment, 2014 Figure 5.8 Dr. Reddy’s: Revenue Breakdown (%) by Region, 2014 Figure 5.9 Dr. Reddy’s: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 5.10 Lupin: Revenue Breakdown (%) by Markets, 2014 Figure 5.11 Lupin: Revenue Breakdown (%) by Therapeutic Area, 2014 Figure 5.12 Lupin: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 5.13 Cipla: Revenue Breakdown (%) by Region, 2014 Figure 5.14 Cipla: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 5.15 Ranbaxy: Revenue Breakdown (%) by Markets, 2014 Figure 5.16 Glenmark: Sales Revenue Increase (%) by Region, 2013-2014 Figure 5.17 Glenmark: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 5.18 Wockhardt: Revenue Breakdown (%) by Region, 2014 Figure 5.19 Ipca: Revenue Breakdown (%) by Therapeutic Area, 2014 Figure 6.1 Top 10 Rest of the World Generic Manufacturers: Revenues ($m), 2014 Figure 6.2 Leading Rest of the World Generic Drug Manufacturers: Gross Profit Margin (%), 2014 Figure 6.3 Leading Rest of the World Generic Drug Manufacturers: EBITDA Margin (%), 2014 Figure 6.4 Leading Rest of the World Generic Drug Manufacturers: AGR (%), 2013-2014 Figure 6.5 Teva: Revenue Breakdown (%) by Business Segment, 2014 Figure 6.6 Teva: Historical Generic Drugs Revenues ($m), AGR (%), 2010-2014 Figure 6.7 Teva: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 6.8 Teva: Revenue Breakdown by Region, 2014 Figure 6.9 Teva: New Generic Drug Launches by Region, 2014 Figure 6.10 Teva: Annual Revenue Change (%) in EU5 Countries, 2013-2014 Figure 6.11 Aspen: Revenue Breakdown (%) by Region, 2013 and 2014 Figure 6.12 Aspen: Revenue Increase (%) by Region, 2014 Figure 6.13 Aspen: European Revenue Breakdown (%) by Region, 2014 Figure 6.14 Aspen: Generic Drugs Revenue Forecast ($m, AGR%), 2015-2025 Figure 6.15 Taro Pharmaceutical: Revenue Breakdown (%) by Region, 2014
Abbott AbbVie Abdi Ibrahim Abrika Pharmaceuticals Ache Actavis Active Pharma Adcock Ingram Advance Vision Research Aegera Afrexa Life Sciences Agouron Pharmaceuticals Akorn Pharmaceuticals Akrikhin Alcon Allergan Alpharma Alvogen AmerisourceBergen Amide Amneal Pharmaceuticals AMS APL Holdings Limited ApoPharma Apotex Apotex Fermentation APP Pharmaceuticals Aprogen Arrow Group Asahi Kasei Pharma Corporation Ascent Pharmahealth ASKA Pharmaceutical Aspen Aspen Pharmacare Aspen Trading AstraZeneca Auden McKenzie Aurigene Discovery Technologies Auro Pharma Aurobindo Balkanpharma Barr Pharmaceuticals Bausch and Lomb Holdings Bayer Bayer Yakuhin BeiKang Pharmaceutical Bever Biocad Holding Bioniche Pharma Biovena Boca Pharmacal Boehringer Ingelheim Brainfarma Industria e Farmaceutica Bremer Pharma Bunker and Delta Cadila Healthcare Cardinal Health Cenova Pharma CFR Pharmaceuticals Chatted Chattem Chemicals Chimpharm Chiron Corporation Chirotech Technology CIBA VISION Cipla CNS Therapeutics Colotech Cosmed Industria de Cosmeticos e Medicamentos S.A. D. Searle & Company Dabur Pharma DACA Pharmaceuticals Daichi Kasei Dialfor Health DKSH Dr. Reddy’s Laboratories Dream Pharma Dusa Pharmaceuticals EBEWE Pharma Elan Pharmaceuticals Elder Pharmaceuticals Emcure Emergent Biosolutions Emploi Quebec European Medicines Agency EMS Endo Eon Labs Ethics Bio Lab Eurofarma Facet Biotech Fako Fenwal Filaxis Fougera Pharmaceuticals Fresenius Kabi Fuso Pharmaceutical Industries Gangene Corp Gedeon Richter Generic Health Generic Pharmaceutical Association (GPhA) Genfar S.A. Genzyme Germa Pharm GlaxoSmithKline (GSK) Glenmark Globalpharma Golden Cross Pharma Greenstone Handok HealthTronics Helvepharm Herbapol Pruszkow Hexa Hikma Hi-Tech Pharmacal Hospira Hypermarcas IDEV Technologies Ikaria Innopharma Inspire Pharmaceuticals Investissement Quebec Ipca Laboratories J-DOLPH Pharmaceutical Johnson & Johnson JPH Group Holdings Kanghong Sagen Pharmaceuticals Keri Pharma Kilitch Drugs Kolmar Holdings Krka Kunwha Pharmaceuticals Kyowa Pharmaceuticals Labesfal Laboratorio Sanderson Laboratorios Gautier Laboratorios Grin Laboratorios Kendrick Labormed Pharma Leek Lekko Les Laboratoires Servier SAS Lotus Pharmaceuticals Lupin mAbxience Madaus Mallinckrodt Maruko Pharmaceutical Masterlek McKesson Drug Company Mechnikov Biomed Mediate Specialities Medina Medisa Shinyaku Medley Industria Farmaceutica Meiji Seika Pharma Merck & Co Microdose Mitani Sangyo Mitsubishi Tanabe Pharma MJ Pharma Multicare Mylan Laboratories Nanomi B.V National Druggists NBZ Pharma Limited Negma Nichi-Iko Nichi-Iko Pharma Tech Nicox Nippon Chemipher Nippon Kayaku NIXS Corporation Novartis Nycomed Oak Pharmaceuticals OctoPlus Omega Laboratories Limited Onset Dermatologics Onyx Oriel Therapeutics Orion Paladin Labs Par Pharmaceutical Parke-Davis Pendopharm Perrigo Company Pfizer PGT Healthcare Pharma Avalanche Pharmacin Pharmapark Pharmascience Pharmascience Korea PharmaSwiss Pharmstandard Pharmstandard Biotec Phlox Pharma Pinewood Laboratories Piramal Healthcare Solutions Polfa Warszawa Polpharma Pradeep Drug Company Promius Pharma Pymepharco Qalitest Questcor Ranbaxy Laboratories Ranbaxy Life Sciences Research Ratiopharm Ribbon Richter-Helm Roche Romark Laboratories Sabex Sagent Acquisition Corp Salix Pharmaceuticals Sandoz Sanofi Sanofi Pasteur Sawai Pharmaceuticals Schein Pharmaceutical Sekisui Medical Shantha Biotechnics Silom Medical Company Sindan Solus Pharmaceuticals Solvay Pharmaceuticals Somar Specifar Pharmaceuticals S.A. SPIL de Mexico Spirig Pharma Stada Arzneimittel STARLIMS Sun Pharmaceutical Swisse Wellness Taiyo Cephalon Taro Technologies Inc Teikoku Medix Terapia S.A. Teva Pharmaceutical Industries The European Generic Medicines Association (EGA) The Generic Pharmaceutical Association TKS Pharmaceutical Torrent Pharmaceuticals Towa UDL Laboratories United Research Laboratories URL Pharma US Food and Drug Administration (FDA) Uteron Pharma S.A. Valeant Velefarm Veropharm VersaPharm Incorporated Vindexpharm VPI Holdings Corp Warner Chilcott Warner Lambert Watson Pharmaceuticals Winthrop Wockhardt Wyeth Yakuhan Pharmaceuticals ZAO Ranbaxy Zao Sun Pharma Zhejiang Chiral Medicine Chemicals Company ZiO Zdorovje Zoetis Zydus Pharmaceuticals Zydus Wellness
Download sample pages
Complete the form below to download your free sample pages for Pharma Leader Series: Top Generic Drug Producers – Leading Companies and Forecasts 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Pharma Leader Series: Top Generic Drug Producers – Leading Companies and Forecasts 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Cancer Diagnostics Market Report 2021-2031
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.
Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
Visiongain Publishes Cell-Based Assays Market Report to 2030
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
